JP2018518151A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518151A5 JP2018518151A5 JP2017550485A JP2017550485A JP2018518151A5 JP 2018518151 A5 JP2018518151 A5 JP 2018518151A5 JP 2017550485 A JP2017550485 A JP 2017550485A JP 2017550485 A JP2017550485 A JP 2017550485A JP 2018518151 A5 JP2018518151 A5 JP 2018518151A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- acid sequence
- isolated
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 49
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 39
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 210000004027 cell Anatomy 0.000 claims description 37
- 150000001413 amino acids Chemical class 0.000 claims description 30
- 150000007523 nucleic acids Chemical group 0.000 claims description 29
- 239000000523 sample Substances 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 15
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 108091033319 polynucleotide Proteins 0.000 claims description 12
- 102000040430 polynucleotide Human genes 0.000 claims description 12
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 238000003364 immunohistochemistry Methods 0.000 claims description 6
- 230000001575 pathological effect Effects 0.000 claims description 6
- 230000011664 signaling Effects 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 238000000684 flow cytometry Methods 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- 238000001262 western blot Methods 0.000 claims description 3
- 241000282465 Canis Species 0.000 claims description 2
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 108091035707 Consensus sequence Proteins 0.000 claims description 2
- 241000282324 Felis Species 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 102000055298 human VTCN1 Human genes 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 238000000338 in vitro Methods 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139592P | 2015-03-27 | 2015-03-27 | |
| US62/139,592 | 2015-03-27 | ||
| PCT/US2016/024357 WO2016160620A2 (en) | 2015-03-27 | 2016-03-25 | Car t-cells for the treatment of b7-h4 expressing solid tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018518151A JP2018518151A (ja) | 2018-07-12 |
| JP2018518151A5 true JP2018518151A5 (OSRAM) | 2019-05-09 |
Family
ID=57007182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550485A Withdrawn JP2018518151A (ja) | 2015-03-27 | 2016-03-25 | Ｂ７−ｈ４発現充実性腫瘍を処置するためのｃａｒ ｔ細胞 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180118831A1 (OSRAM) |
| EP (1) | EP3274369A4 (OSRAM) |
| JP (1) | JP2018518151A (OSRAM) |
| CN (1) | CN107531782A (OSRAM) |
| AU (1) | AU2016243126A1 (OSRAM) |
| CA (1) | CA2981143A1 (OSRAM) |
| IL (1) | IL254700A0 (OSRAM) |
| WO (1) | WO2016160620A2 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10814011B1 (en) | 2017-06-16 | 2020-10-27 | Nantbio, Inc. | Anti-B7-H4 antibodies and methods |
| JP2020530277A (ja) | 2017-06-30 | 2020-10-22 | セレクティスＣｅｌｌｅｃｔｉｓ | 反復投与のための細胞免疫療法 |
| UA128472C2 (uk) | 2017-08-25 | 2024-07-24 | Файв Прайм Терапеутікс Інк. | B7-h4 антитіла і методи їх використання |
| CN107903326B (zh) * | 2018-01-02 | 2020-06-30 | 广东省人民医院(广东省医学科学院) | 包含C3aR胞内结构域的嵌合抗原受体、慢病毒载体、表达细胞及药物 |
| CN110366560B (zh) * | 2018-02-11 | 2023-07-28 | 江苏豪森药业集团有限公司 | 抗b7-h4抗体、其抗原结合片段及其医药用途 |
| BR112020016986A2 (pt) | 2018-02-21 | 2021-03-02 | Five Prime Therapeutics, Inc. | formulações de anticorpo contra b7-h4 |
| CA3091801A1 (en) | 2018-03-02 | 2019-09-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| WO2020187327A1 (en) * | 2019-03-21 | 2020-09-24 | Suzhou Kanova Biopharmaceutical Co. Ltd. | Anti-b7s1 polypeptides and their use |
| AU2019459423B2 (en) * | 2019-08-01 | 2023-06-01 | Immunitybio, Inc. | Anti-B7-H4 chimeric antigen receptor-modified NK-92 cells |
| US20230192807A1 (en) * | 2020-05-15 | 2023-06-22 | Precision Biosciences, Inc. | Methods for immunotherapy |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN113156120B (zh) * | 2021-03-26 | 2022-03-25 | 中国医学科学院北京协和医院 | B7h4在制备子宫内膜癌分子分型试剂及系统中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6468546B1 (en) * | 1998-12-17 | 2002-10-22 | Corixa Corporation | Compositions and methods for therapy and diagnosis of ovarian cancer |
| WO2006055178A2 (en) * | 2004-10-25 | 2006-05-26 | Merck & Co., Inc. | Anti-addl antibodies and uses thereof |
| US7858752B2 (en) * | 2006-12-05 | 2010-12-28 | Abbott Laboratories | Recombinant antibodies against hepatitis C virus and methods of obtaining and using same |
| AU2010254136B2 (en) * | 2009-05-26 | 2016-09-29 | Mount Sinai School Of Medicine | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
| EP2773651B1 (en) * | 2011-11-03 | 2020-12-23 | The Trustees of the University of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
| WO2013130565A1 (en) * | 2012-02-29 | 2013-09-06 | The Brigham And Women's Hosptial, Inc. | Neutralizing antibody for epstein barr virus associated disease |
| EP2906598A1 (en) * | 2012-10-09 | 2015-08-19 | Igenica Biotherapeutics, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
| EP2934575A2 (en) * | 2012-12-19 | 2015-10-28 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| AU2014244424A1 (en) * | 2013-03-14 | 2015-08-27 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| JP6288621B2 (ja) * | 2013-08-23 | 2018-03-07 | 学校法人藤田学園 | インフルエンザウイルスに対する抵抗力の判定方法 |
-
2016
- 2016-03-25 JP JP2017550485A patent/JP2018518151A/ja not_active Withdrawn
- 2016-03-25 WO PCT/US2016/024357 patent/WO2016160620A2/en not_active Ceased
- 2016-03-25 CA CA2981143A patent/CA2981143A1/en not_active Abandoned
- 2016-03-25 CN CN201680024423.4A patent/CN107531782A/zh active Pending
- 2016-03-25 AU AU2016243126A patent/AU2016243126A1/en not_active Abandoned
- 2016-03-25 EP EP16773873.1A patent/EP3274369A4/en not_active Withdrawn
- 2016-03-25 US US15/561,968 patent/US20180118831A1/en not_active Abandoned
-
2017
- 2017-09-26 IL IL254700A patent/IL254700A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018511319A5 (OSRAM) | ||
| JP2018518151A5 (OSRAM) | ||
| CN112154157B (zh) | 抗ror1抗体及其用途 | |
| KR20210099052A (ko) | 항-pd-l1/항-4-1bb 이중특이적 항체 및 이의 용도 | |
| Fisher et al. | Generation and preclinical characterization of an antibody specific for SEMA4D | |
| KR102346988B1 (ko) | 항 b7-h4 항체 | |
| TWI878541B (zh) | 抗ｃｌｄｎ１８.２抗體及其診斷用途 | |
| JP2012012402A5 (OSRAM) | ||
| JP2018524973A5 (OSRAM) | ||
| CN118459593A (zh) | 抗b7-h3抗体及其用途 | |
| JP2018518152A5 (OSRAM) | ||
| CN111995682B (zh) | 抗人SIRPα单克隆抗体及其用途 | |
| JP2013506428A5 (OSRAM) | ||
| JP2014527398A5 (OSRAM) | ||
| JP2018505681A5 (OSRAM) | ||
| TW201829467A (zh) | 抗ｃｄ３抗體及含有該抗體的分子 | |
| JP2020513769A (ja) | 抗ｌａｉｒ１抗体およびその使用 | |
| JP2020501512A5 (OSRAM) | ||
| WO2021097800A1 (en) | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof | |
| CN111620949A (zh) | 结合人lag-3的抗体、其制备方法和用途 | |
| CN115298543A (zh) | 抗原抗体特异性结合识别方法 | |
| EP3589652A1 (en) | Recombinant antibodies to programmed death 1 (pd-1) and uses therefor | |
| CN113683697B (zh) | 抗b7-h3抗体、其制备方法及用途 | |
| TW202233677A (zh) | Bcma/taci抗原結合分子 | |
| JPWO2014192974A1 (ja) | 抗ｌｇｒ６抗体を含む癌の検出用又は診断用試薬 |